ZURA BIO LIMITED Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
ZURA BIO LIMITED (ZURA) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$52.40 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2025-03-25
- ZURA BIO LIMITED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-12-31 was -$13.63M.
- ZURA BIO LIMITED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$20.70M.
- ZURA BIO LIMITED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$10.33M.
- ZURA BIO LIMITED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was -$7.75M.
- ZURA BIO LIMITED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$52.40M.
- ZURA BIO LIMITED income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$60.56M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 2 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 5 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 8 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 11 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$13.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$34.33M derived: sum of 2 quarters · filed 2025-03-25 | -$44.66M derived: sum of 3 quarters · filed 2025-03-25 | -$52.40M 10-K · filed 2025-03-25 | ||||
| 2024-09-30 | -$20.70M 10-Q · filed 2024-11-07 | -$31.03M derived: sum of 2 quarters · filed 2024-11-07 | -$38.78M 10-Q · filed 2024-11-07 | -$47.25M derived: sum of 4 quarters · filed 2025-03-25 | ||||
| 2024-06-30 | -$10.33M 10-Q · filed 2024-08-13 | -$18.08M 10-Q · filed 2024-08-13 | -$26.55M derived: sum of 3 quarters · filed 2025-03-25 | -$34.82M derived: sum of 4 quarters · filed 2025-03-25 | ||||
| 2024-03-31 | -$7.75M 10-Q · filed 2024-05-09 | -$16.22M derived: sum of 2 quarters · filed 2025-03-25 | -$24.49M derived: sum of 3 quarters · filed 2025-03-25 | -$58.52M derived: sum of 4 quarters · filed 2025-03-25 | ||||
| 2023-12-31 | -$8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$16.74M derived: sum of 2 quarters · filed 2025-03-25 | -$50.77M derived: sum of 3 quarters · filed 2025-03-25 | -$60.56M 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | -$8.27M 10-Q · filed 2024-11-07 | -$42.30M derived: sum of 2 quarters · filed 2024-11-07 | -$52.09M 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | -$34.02M 10-Q · filed 2024-08-13 | -$43.82M 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | -$9.79M 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | -$27.33M 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | -$1.10M 10-Q · filed 2023-11-13 | -$2.03M derived: sum of 2 quarters · filed 2023-11-13 | -$9.85M 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | -$925.00K 10-Q · filed 2023-08-14 | -$8.74M 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | -$7.82M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |